348 THE ADVOCATE
VOL. 79 PART 3 MAY 2021
director and to move the existing clinic to the Djavad Mowafaghian Centre
for Brain Health at UBC (a research centre that also has clinics for all other
major neurological diseases, like Huntington and Alzheimer’s disease).
We can do this. In March and April 2021, the B.C. government issued
ICBC rebate cheques averaging $190 per person, for a total of approximately
$600 million. If everyone in B.C. agreed to donate five per cent of their
cheque (less than $10), we could raise $30 million for ALS research and clinical
This would be an unprecedented amount of funding in Canada.
My story is not the only ALS story. ALS Action Canada currently has over
50 member families from coast to coast, each with their own story of devastation,
courage and hope, and each advocating for ALS. You can find many
of their stories, as well as our full plan to improve ALS treatment and
research in Canada, on our website.
I am incredibly grateful for the support I’ve already received from so
many friends and colleagues in the legal community. Everything you have
done, and will do, to help #EndALS is so appreciated by me and the other
3,000 families in Canada impacted by the terrible disease that is ALS.
Truly meaningful research is being done, and we are getting closer than
ever to a cure. After 160 years of this terrible disease, and 80 years since Lou
Gehrig died, now is the time to make it happen.
It’s time to finally #EndALS, so no one will ever have to go through what
my family and I are going through, ever again.
1. Online: <www.alsactioncanada.org>.
2. Amylyx Pharmaceuticals, Inc., News Release, “Amylyx
Pharmaceuticals Plans Regulatory Filing of
AMX0035 for the Treatment of ALS in Canada” (9
March 2021), online: <www.businesswire.com/
3. ALS Action Canada, News Release, “ALS Action
Canada Issues Media Release Urging Health
Canada and the Provinces to Swiftly Approve
AMX0035” (10 March 2021), online: <alsaction
4. ALS Action Canada, “Help #EndALS Now!”, online: